comprehensive -WSS

comprehensive

author：explore 2025-10-01 02:15:17 - browse：4

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Did the public have the right to know Arthur Ashe had AIDS?

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

When is a doctor not a doctor? Try when patients address women doctors

RaDonda Vaught case: a double standard for nurses, physicians

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Why is France rioting? What to know about the fatal police shooting of Nahel M

Community addresses injustice for Long Island mothers

hotspot

comprehensive

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Can food be medicine? And other questions about a new push

Jerome Adams on the need for new antivirals for Covid

A daunting task: navigating dual Medicare, Medicaid eligibility

Medical leaders decry Supreme Court decision on affirmative action

In key trial, Verve's treatment lowers cholesterol levels in patients

Psychedelics group wrestles with new pharma identity

Inside the fall of star MIT scientist David Sabatini

Psychedelics group wrestles with new pharma identity

PhRMA sues HHS over Medicare drug price negotiation

knowledge

Why medical students are struggling with mental health

Ransomware attacks on hospitals: Study outlines patient impact

Does good food count as health care? Study aims to find out

Astellas still sees hope in its gene therapy after four deaths

Wegovy, Zepbound and weight loss drugs that preserve muscle

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

hotspot

entertainment

leisure time

leisure time